Trial · NCT07886476
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety: Incidence of adverse events (AEs) and serious adverse events (SAEs) following a single dose of IBI3034 in healthy participants(Part 1) | through study completion,an average of 169 days | |
| Primary | Safety: Incidence of AEs and SAEs following multiple doses of IBI3034 in participants with primary IgA nephropathy(Part 2) | through study completion,an average of 252 days | |
| Secondary | Pharmacodynamic (PD) Profile: Change from baseline in serum immunoglobulin levels(Part 1) | through study completion,an average of 169 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in UPCR(Part2) | through study completion,an average of 252 days | |
| Secondary | Pharmacodynamic (PD) Profile: Change from baseline in serum immunoglobulin levels (Part 2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in UACR (Part 2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in eGFR (Part 2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in hematuria(Part2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in serum albumin(Part2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in serum creatinine(Part2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in blood pressure (both systolic and diastolic)(Part2) | through study completion,an average of 252 days | |
| Secondary | Maximum Concentration, Cmax (Part 1) | through study completion,an average of 57 days | |
| Secondary | Time to Reach Peak Plasma Concentration (Tmax)(Part 1) | through study completion,an average of 57 days | |
| Secondary | Apparent Clearance (CL/F) (Part 1) | through study completion,an average of 57 days | |
| Secondary | Apparent Volume of Distribution (Vz/F) (Part 1) | through study completion,an average of 57 days | |
| Secondary | Terminal Half-Life (T1/2) (Part 1) | through study completion,an average of 57 days | |
| Secondary | Area Under the Concentration-Time Curve, AUC (Part 1) | through study completion,an average of 57 days | |
| Secondary | Maximum Concentration, Cmax (Part 2) | through study completion,an average of 156 days | |
| Secondary | Time to Reach Peak Plasma Concentration (Tmax)(Part 2) | through study completion,an average of 156 days | |
| Secondary | Apparent Clearance (CL/F) (Part 2) | through study completion,an average of 156 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07886476/registered